Navigation Links
EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
Date:9/13/2013

The EORTC will have an active presence at the 2013 ECCO-ESMO-ESTRO Meeting in Amsterdam, The Netherlands, from 27 September to 01 October 2013 and would like to call your attention to the following presentations.

Society Session

F. Meunier and R. Stupp are co-Chairs of the session "European Organisation for Research and Treatment of Cancer (EORTC) - Multidisciplinary Cancer Clinical Research: What are we up to in 2013?" on Saturday, 28 September 2013 from 16:00 - 18:00 in Room G102.

Special sessions

J. Bogaerts will chair a Special session, "Dilemma of Crossover in Clinical Trial Design of Agents with 'Obvious Activity'" On Saturday, 28 September 2013 from 14:15 15:15 in Elicium 1. During this session he will also present "Cross over in oncology trials: Considerations for endpoints and trial design - arguments pro and contra".

S. Litire will present "Data warehouse and uncertainties in response measurements" in a special session on Tumor Response Assessment on Sunday, 29 September at 13:25 in Room E102.

Debates

F. Meunier will speak in favor during the Regulatory/Trial Methodology/Pharmacy debate, "This House Believes That the EU Clinical Trials Directive has Harmed European Clinical Studies" on Monday, 30 September 2013 from 17:00 18:00 in Room D201.

L. Collette will present as a seconder against in a debate entitled "This House Believes That New Technologies in RT do not Require Randomised Clinical Trials" on Monday, 30 September from 17:00 18:00 in Hall 3.2.

General Sessions

J. Bogaerts, EORTC Methodology Vice Director, will present "Statistical considerations in the evaluation of biomarkers" during the FLIMS Alumni Club Workshop on Monday, 30 September 2013 at 11:35 in Room E107.

Oral Poster Presentations

Philip Poortmans, Henk Struikmans, Carine Kirkove, Volker Budach, Philippe Maingon, Maria Carla Valli, Sandra Collette, Alain Fourqu
'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
2. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
5. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
6. EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
7. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
8. EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
9. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
10. Targeted therapeutics for colon cancer to be presented at AACR meeting
11. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... NEW YORK (PRWEB) , ... August 31, 2015 , ... ... for anti-aging products for men and barbershops are scrambling to meet it. , Reports ... get information for hairstyles and haircare. But the data also reflects that men are ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... for physicians and allied health professionals dedicated to using lifestyle as a ... the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, with ...
(Date:8/31/2015)... ... August 31, 2015 , ... Westchester Insurance, a full service ... up with the Tarrant County chapter of Meals on Wheels to provide healthy ... oldest and largest national organization that supports the more than five thousand nutrition ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based ... with Bright Pink® to raise money and awareness for breast and ovarian health. ... Hot Pink Sassy incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, ...
(Date:8/31/2015)... ... ... There’s big news for ZendyHealth , a Los Angeles-based startup company ... health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought on two experts ... another to answer customers’ questions directly. , John Young, CEO of Consumerdriven, LLC will ...
Breaking Medicine News(10 mins):Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... magazine has reported that cancer patients have been buying an untried ... illness//. The drug called DCA, short form for dichlroacetate has been ... has not been tested in humans so far. ,Understandably, ... in humans and it has been reported that around two hundred ...
... 29 (DPA) A Serbian patient has survived more than a ... Belgrade daily Blic reported Thursday.// ,The gauze was ... a spokesman of the Sremska Kamenica cardiovascular institute, 70 km ... ,It was found during surgery in mid-March. The latter operation ...
... millions of Americans whose vision is slowly ebbing due to ... may be riding to the rescue. ,In a ... stem cells have been shown to protect the vision of ... diseases that afflict humans. The new study appears today (March ...
... found mainly in partially hydrogenated vegetable oils and widely ... an increased risk of coronary heart disease (CHD). ... use in restaurants, and other cities are considering similar ... Public Health (HSPH) provides the strongest association to date ...
... Patricia Hewitt, the health secretary said that computer based ... depression and anxiety//. This will be available to all ... programs- Fear fighter and Beating the blues have been ... However, health experts have warned that computer aided programs ...
... can do more than making you look like one. It steers ... are a woman//, say researchers. , The report published ... by lead author Dr. David W. Dunstan and team from the ... data from people who confessed to sedentary lives ruled by lots ...
Cached Medicine News:Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Higher Trans Fat Levels in Blood Associated With Elevated Risk of Heart Disease 2Health News:Computer Based Therapy For Depression 2Health News:Sedentary Lives Equal Shorter ‘sweeter’ Liv 2
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... NEW YORK, Nov. 15, 2011 Reportlinker.com ... is available in its catalogue: ... East Asia ... analysis of four pharmaceutical markets that present ...
... SuccessEHS Director of Client Services Elizabeth Pharo will serve as ... This breakout session on Nov. 17 will highlight concrete examples ... have led to care improvements. The panel session is part ... Information Technology (ONC) Annual Meeting that will take place Nov. ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4SuccessEHS Director of Client Services to Serve as Panelist at ONC Annual Meeting 2SuccessEHS Director of Client Services to Serve as Panelist at ONC Annual Meeting 3
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Medicine Products: